Skip to main content
. 2021 Oct 14;107(6):1397–1409. doi: 10.3324/haematol.2021.279229

Figure 1.

Figure 1.

Progression-free survival with isatuximab (Isa) carfilzomib (K) dexamethasone (d) (Isa-Kd) compared with Kd. (A) Patients with renal impairment (RI) (eGFR <60 mL/min/1.73 m²) or (B) without RI (eGFR ≥60 mL/min/1.73 m²), (ITT population). Progression-free survival (PFS) as per blinded independent response committee. d: dexamethasone; eGFR: estimated glomerular filtration rate; Isa: isatuximab; ITT: intent to treat; K: carfilzomib; PFS: progression-free survival.